Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Expectoration | Research

Time to sputum culture conversion and its associated factors among drug-resistant tuberculosis patients: a systematic review and meta-analysis

Authors: Yang Wenlu, Zhao Xia, Wu Chuntao, Yu Qiaolin, Xiao Xujue, Yao Rong, Su Dan, Yan Xi, Wan Bin

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Objective

We aimed to evaluate the sputum culture conversion time of DR-TB patients and its related factors.

Methods

PubMed, The Cochrane Library, Embase, CINAHL, Web of Science, CNKI, Wan Fang, CBM and VIP databases were electronically searched to collect studies on sputum culture conversion time in patients with DR-TB. Meta-analysis was performed by using the R 4.3.0 version and Stata 16 software.

Results

A total of 45 studies involving 17373 patients were included. Meta-analysis results showed that the pooled median time to sputum culture conversion was 68.57 days (IQR 61.01,76.12). The median time of sputum culture conversion in patients with drug-resistant tuberculosis was different in different WHO regions, countries with different levels of development and different treatment schemes. And female (aHR = 0.59,95%CI: s0.46,0.76), alcohol history (aHR = 0.70,95%CI:0.50,0.98), smoking history (aHR = 0.58,95%CI:0.38,0.88), history of SLD use (aHR = 0.64,95%CI:0.47,0.87), BMI < 18.5 kg/m2 (aHR = 0.69,95%CI:0.60,0.80), lung cavity (aHR = 0.70,95%CI:0.52,0.94), sputum smear grading at baseline (Positive) (aHR = 0.56,95%CI:0.36,0.87), (grade 1+) (aHR = 0.87,95%CI:0.77,0.99), (grade 2+) (aHR = 0.81,95%CI:0.69,0.95), (grade 3+) (aHR = 0.71,95%CI:0.61,0.84) were the related factor of sputum culture conversion time in patients with DR-TB.

Conclusion

Patients with DR-TB in Europe or countries with high level of economic development have earlier sputum culture conversion, and the application of bedaquiline can make patients have shorter sputum culture conversion time. Female, alcohol history, smoking history, history of SLD use, BMI < 18.5 kg/m2, lung cavity, sputum smear grading at baseline (Positive, grade 1+, grade 2+, grade 3+) may be risk factors for longer sputum culture conversion time.
This systematic review has been registered in PROSPERO, the registration number is CRD42023438746.
Appendix
Available only for authorised users
Literature
2.
go back to reference Chaves Torres NM, Quijano Rodriguez JJ, Porras Andrade PS, et al. Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. PLoS One. 2019;14(12):e0226507.CrossRefPubMedPubMedCentral Chaves Torres NM, Quijano Rodriguez JJ, Porras Andrade PS, et al. Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. PLoS One. 2019;14(12):e0226507.CrossRefPubMedPubMedCentral
3.
go back to reference Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147–54.CrossRefPubMedPubMedCentral Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147–54.CrossRefPubMedPubMedCentral
4.
go back to reference Velayutham B, Nair D, Kannan T, et al. Factors associated with sputum culture conversion in multidrugresistant pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):1671–6.CrossRefPubMed Velayutham B, Nair D, Kannan T, et al. Factors associated with sputum culture conversion in multidrugresistant pulmonary tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):1671–6.CrossRefPubMed
6.
go back to reference Iqbal Z, Khan MA, Aziz A, et al. Time for culture conversion and its associated factors in multidrug-resistant tuberculosis patients at a tertiary level hospital in Peshawar, Pakistan. Pakistan J Med Sci. 2022;38(4Part-II):1009. Iqbal Z, Khan MA, Aziz A, et al. Time for culture conversion and its associated factors in multidrug-resistant tuberculosis patients at a tertiary level hospital in Peshawar, Pakistan. Pakistan J Med Sci. 2022;38(4Part-II):1009.
7.
go back to reference YihunieAkalu T, FentahunMuchie K, Alemu Gelaye K. Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: A multicenter retrospective follow up study. PLoS One. 2018;13(6):e0199320.CrossRef YihunieAkalu T, FentahunMuchie K, Alemu Gelaye K. Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: A multicenter retrospective follow up study. PLoS One. 2018;13(6):e0199320.CrossRef
8.
go back to reference Assemie MA, Alene M, Petrucka P, et al. Time to sputum culture conversion and its associated factors among multidrug-resistant tuberculosis patients in Eastern Africa: A systematic review and meta-analysis. Int J Infect Dis. 2020;98:230–6.CrossRefPubMed Assemie MA, Alene M, Petrucka P, et al. Time to sputum culture conversion and its associated factors among multidrug-resistant tuberculosis patients in Eastern Africa: A systematic review and meta-analysis. Int J Infect Dis. 2020;98:230–6.CrossRefPubMed
9.
go back to reference Chinese Antituberculosis Association. Guidelines for chemotherapy of drug-resistant tuberculosis (2019 edition). Chin J of Antituber, 2019;41(10):1025–73. Chinese Antituberculosis Association. Guidelines for chemotherapy of drug-resistant tuberculosis (2019 edition). Chin J of Antituber, 2019;41(10):1025–73.
10.
go back to reference Wells GA, Shea B, O’Connell D, et al. The New- castle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford: The Ottawa Hospital Research Institute; 2000. Wells GA, Shea B, O’Connell D, et al. The New- castle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford: The Ottawa Hospital Research Institute; 2000.
12.
go back to reference Myers B, Bouton TC, Ragan EJ, et al. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infect Dis. 2018;18:1–9.CrossRef Myers B, Bouton TC, Ragan EJ, et al. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infect Dis. 2018;18:1–9.CrossRef
13.
go back to reference Russkikh A, Korotych O, Sereda Y, et al. Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study. Monaldi Arch Chest Dis. 2021;91(1):1678. Russkikh A, Korotych O, Sereda Y, et al. Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study. Monaldi Arch Chest Dis. 2021;91(1):1678.
14.
go back to reference Javaid A, Ahmad N, Afridi AK, et al. Validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: a retrospective single-center study. Am J Trop Med Hyg. 2018;98(6):1629.CrossRefPubMedPubMedCentral Javaid A, Ahmad N, Afridi AK, et al. Validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: a retrospective single-center study. Am J Trop Med Hyg. 2018;98(6):1629.CrossRefPubMedPubMedCentral
15.
go back to reference Diktanas S, Korotych O, Sereda Y, et al. Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study. Monaldi Arch Chest Dis. 2021;91(1):1675. Diktanas S, Korotych O, Sereda Y, et al. Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study. Monaldi Arch Chest Dis. 2021;91(1):1675.
16.
go back to reference Batool R, Khan SW, Imran M, et al. Culture conversion and six months interim outcomes in retreatment cases of pulmonary MDRTB—a six month interim analysis. J Pak Med Assoc. 2021;71(12):2710–6.PubMed Batool R, Khan SW, Imran M, et al. Culture conversion and six months interim outcomes in retreatment cases of pulmonary MDRTB—a six month interim analysis. J Pak Med Assoc. 2021;71(12):2710–6.PubMed
17.
go back to reference Wagnew F, Alene KA, Kelly M, et al. The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2023;127:93–105. Wagnew F, Alene KA, Kelly M, et al. The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2023;127:93–105.
18.
go back to reference Gamachu M, Deressa A, Birhanu A, et al. Sputum smear conversion and treatment outcome among drug-resistant pulmonary tuberculosis patients in Eastern Ethiopia, 2022: a nine-year data. Front Med. 2022;12:3493. Gamachu M, Deressa A, Birhanu A, et al. Sputum smear conversion and treatment outcome among drug-resistant pulmonary tuberculosis patients in Eastern Ethiopia, 2022: a nine-year data. Front Med. 2022;12:3493.
19.
go back to reference Basit A, Ahmad N, Khan AH, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS One. 2014;9(4):e93206.ADSCrossRefPubMedPubMedCentral Basit A, Ahmad N, Khan AH, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS One. 2014;9(4):e93206.ADSCrossRefPubMedPubMedCentral
20.
go back to reference Butov D, Myasoedov V, Gumeniuk M, et al. Treatment effectiveness and outcome in patients with a relapse and newly diagnosed multidrug-resistant pulmonary tuberculosis. Med Glas (Zenica). 2020;17(2):356–62. Butov D, Myasoedov V, Gumeniuk M, et al. Treatment effectiveness and outcome in patients with a relapse and newly diagnosed multidrug-resistant pulmonary tuberculosis. Med Glas (Zenica). 2020;17(2):356–62.
21.
go back to reference Restrepo BI, Fisher-Hoch SP, Smith B, et al. Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes. Am J Trop Med Hyg. 2008;79(4):541.CrossRefPubMed Restrepo BI, Fisher-Hoch SP, Smith B, et al. Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes. Am J Trop Med Hyg. 2008;79(4):541.CrossRefPubMed
22.
go back to reference Tekalegn Y, Woldeyohannes D, Assefa T, et al. Predictors of time to sputum culture conversion among drug-resistant tuberculosis patients in Oromia Region Hospitals, Ethiopia. Infect Drug Resist. 2020;13:2547–56.CrossRefPubMedPubMedCentral Tekalegn Y, Woldeyohannes D, Assefa T, et al. Predictors of time to sputum culture conversion among drug-resistant tuberculosis patients in Oromia Region Hospitals, Ethiopia. Infect Drug Resist. 2020;13:2547–56.CrossRefPubMedPubMedCentral
23.
go back to reference Jafri S, Ahmed N, Saifullah N, et al. Liaison of sugar control with time to sputum culture conversion in multi-drug resistant tuberculosis. Cureus. 2020;12(7):e9395.PubMedPubMedCentral Jafri S, Ahmed N, Saifullah N, et al. Liaison of sugar control with time to sputum culture conversion in multi-drug resistant tuberculosis. Cureus. 2020;12(7):e9395.PubMedPubMedCentral
24.
go back to reference Bade AB, Mega TA, Negera GZ. Malnutrition is associated with delayed sputum culture conversion among patients treated for MDR-TB. Infect Drug Resist. 2021;14:1659–67.CrossRefPubMedPubMedCentral Bade AB, Mega TA, Negera GZ. Malnutrition is associated with delayed sputum culture conversion among patients treated for MDR-TB. Infect Drug Resist. 2021;14:1659–67.CrossRefPubMedPubMedCentral
Metadata
Title
Time to sputum culture conversion and its associated factors among drug-resistant tuberculosis patients: a systematic review and meta-analysis
Authors
Yang Wenlu
Zhao Xia
Wu Chuntao
Yu Qiaolin
Xiao Xujue
Yao Rong
Su Dan
Yan Xi
Wan Bin
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09009-5

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.